Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Spectranetics touts Stellarex drug-eluting balloon data
Spectranetics is touting 2-year data, published in the journal Catheterization & Cardiovascular Interventions, on the Stellarex the drug-eluting balloon it bought from Covidien early this year.
Data from the 78-patient Illumenate 1st-in-human study showed primary patency rates of 89.5% at 1 year and 80.3% at 2 years, Colorado Springs, Colo.-based Spectranetics said. The rate of freedom from clinically driven target lesion revascularization was 90.0% after a year and 85.8% at 24 months, according to the company. Read more
2. Boston Scientific touts S-ICD data from long-term safety & efficacy study
Boston Scientific touted a study published in the Journal of the American College of Cardiology showing the long-term safety and effectiveness of its S-ICD “leadless” defibrillator.
The study pooled 6-month to 1-year data from a pair of Boston Scientific-funded clinical trials, the S-ICD investigational device exemption trial and the Effortless post-market trial. Read more
1. Tal Medical raises $14m for non-invasive anti-depression device
Tal Medical said today that it landed a $14 million Series B round it plans to use in backing clinical trials for its low-field magnetic stimulation technology as a non-invasive neurostimulation treatment for depression and bipolar disorder.
Boston-based Tal Medical said existing backer PureTech, a new institutional investor and several “prominent” but unnamed individual investors. The cash will also go toward product development and to “scale up the organization,” Tal said. Read more
